
Ventas (VTR) Stock Forecast & Price Target
Ventas (VTR) Analyst Ratings
Bulls say
Ventas maintains a diversified healthcare portfolio of nearly 1,400 properties across various segments, which positions the firm for robust growth, with potential EBITDAR doubling from approximately $50 million to $100 million over time. The in-place net asset value (NAV) is estimated to increase significantly from $55.85 per share at year-end 2025 to $63.15 per share by year-end 2026, reflecting a positive growth trajectory. Furthermore, Ventas is well-equipped to capitalize on favorable seniors housing trends and implement its strong investment strategy, underscored by an expanding pipeline of high-quality opportunities, enhancing the company's operational outlook.
Bears say
The negative outlook on Ventas's stock is primarily driven by the worsening cost of capital and management's potential inability to pursue new investment opportunities, which could lead to a lower adjusted funds from operations (AFFO) estimate. Additionally, a muted growth outlook for the seniors housing operating portfolio (SHOP) indicates that occupancy improvements may be limited, with revenue per occupied room (REVPOR) growth and expenses largely offsetting one another. Furthermore, the company's net debt to EBITDA ratio stands at 5.7x, exceeding the target range of 5.0–6.0x, and potential reductions in Medicare and Medicaid reimbursements raise concerns about rent coverage ratios.
This aggregate rating is based on analysts' research of Ventas and is not a guaranteed prediction by Public.com or investment advice.
Ventas (VTR) Analyst Forecast & Price Prediction
Start investing in Ventas (VTR)
Order type
Buy in
Order amount
Est. shares
0 shares